TORL BioTherapeutics' CLDN6-Targeting Antibody-Drug Conjugate Demonstrates Encouraging Early Results
Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ...
The firm is testing azenosertib as a single agent and in combination with other drugs in various solid tumors and looking at response biomarkers.
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.
The company recently discovered this gene signature in a large dataset of patients treated with a marketed a4β7 integrin antibody for ulcerative colitis.
Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...
The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...
The results, published in Nature, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line ...
Using Herceptin as an example, Andre Ilbawi detailed the challenges low- and medium-income countries face in accessing essential therapies.
A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid ...
The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.
The Phase II results bolster the firm's confidence in the c-MET expression cutoff it has established in an ongoing Phase III trial of the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback